Who Paid My Doc
A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effec
Research payments
$657,721
Through program year 2024, $657,721 in research payments was reported against A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effec, across 170 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $11,460 | 7 |
| 2023 | Research | $154,655 | 64 |
| 2022 | Research | $491,606 | 99 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- William Sanchez Miami Lakes, FL Named on 19 payments
- Mark Carlson Round Rock, TX Named on 16 payments
- Clint Flanagan Fort Collins, CO Named on 16 payments
- Michael Butcher Cincinnati, OH Named on 12 payments
- Dennis Morrison Springfield, MO Named on 10 payments
- Manohar Jethani Berwyn, IL Named on 10 payments
- Todd Vasko Charleston, SC Named on 9 payments
- Charles Andrews San Antonio, TX Named on 7 payments
- Pedro Reimon Miami, FL Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.